FindTrial
Sign In

A study for the effect of aliskiren on endothelial progenitor cells in patients with hypertension

A study for the effect of aliskiren on endothelial progenitor cells in patients with hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017739
Enrollment
Unknown
Registered
2018-08-11
Start date
2018-08-13
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Case group:drug(aliskiren)
Normal control group:Nil

Sponsors

The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: The normal blood pressure and hypertension adult male volunteers (diagnostic criteria referred to seventh report of the joint national committee (JNC8)) were divided into the control group and the hypertension group. The two groups had to match the age with the body mass index (BMI), no other cardiovascular disease and high blood pressure related medicine treatment before. The study was all informed consent.

Exclusion criteria

Exclusion criteria: Known cardiovascular disease, diabetes, malignant tumor, acute or chronic infection, or inflammatory disease; people who have taken antiplatelet, anti inflammatory and lipid lowering drugs recently; smokers.

Design outcomes

Primary

MeasureTime frame
the number of endothelial progenitor cells;—

Countries

China

Contacts

Public ContactYang Zhen

The First Affiliated Hospital, Sun Yat-sen University

yangzhen10710710@163.com+86 13711234169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026